ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Alpha Healthcare Acquisition Corporation

Alpha Healthcare Acquisition Corporation (AHAC)

10,96
0,00
(0,00%)
Fermé 25 Août 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
10,96
Prix Achat
10,75
Prix Vente
10,96
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
10,96
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
206 578 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-20,44
Bénéfice par action (BPA)
-0,54
Chiffre d'affairess
-
Bénéfice net
-110,78M

À propos de Alpha Healthcare Acquisition Corporation

Alpha Healthcare Acquisition Corp is a blank check company. Alpha Healthcare Acquisition Corp is a blank check company.

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
Siège social
Wilmington, Delaware, USA
Fondé
1970

AHAC Dernières nouvelles

Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021Company well-positioned to deliver...

Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its...

Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs

Appoints proven commercial leader B.J. Scheessele as Chief Commercial OfficerIn-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale...

Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes

Data demonstrate biovascular pancreas may have the potential to provide an effective and safe method for pancreatic islet cell transplantation for the treatment of type 1 diabetes Data published...

Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination

Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc. to be held August 24, 2021, at 10:00 a.m. EDTShareholders as of the close of...

Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 – Replace, Repair, Regenerate Planning Workshop

DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale...

UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Partnership expanded to include vascular trauma repair outside of the United States.Fresenius Medical Care is a leading participant in fully committed PIPE financing transaction. DURHAM, N.C...

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Partnership expanded to include vascular trauma repair outside of the United States.Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and...

Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment

Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patientsData presented...

Humacyte to Provide Investor Update on June 7

DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PRTGPortage Biotech Inc
US$ 5,90
(118,49%)
49,67M
MNTSMomentus Inc
US$ 1,04
(80,65%)
231,74M
GHSIGuardion Health Sciences Inc
US$ 17,91
(58,50%)
561,42k
RETOReTo Eco Solutions Inc
US$ 1,591
(52,98%)
3,45M
HUBCWHub Cyber Security Ltd
US$ 0,0149
(40,57%)
40,79k
UBXGU BX Technology Ltd
US$ 2,38
(-92,54%)
35,79M
FAMIFarmmi Inc
US$ 0,2336
(-58,76%)
14,1M
GDCGD Culture Group Ltd
US$ 5,43
(-29,94%)
28,75M
NUWENewellis Inc
US$ 1,26
(-26,74%)
754,69k
TGLTreasure Global Inc
US$ 0,85
(-25,44%)
1,4M
NVDANVIDIA Corporation
US$ 129,37
(4,55%)
323,23M
MNTSMomentus Inc
US$ 1,04
(80,65%)
231,74M
SQQQProShares UltraPro Short QQQ
US$ 7,98
(-3,16%)
186,3M
MULNMullen Automotive Inc
US$ 0,3321
(-7,62%)
140,97M
APDNApplied DNA Sciences Inc
US$ 2,4901
(36,07%)
127,34M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock